Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1958 articles with Sanofi (France)
-
The approval marks the first for EoE, a chronic, progressive type 2 inflammatory disease that damages the eosinophilic esophagitis and prevents it from working properly.
-
RQ Biotechnology has officially launched, with the financial backing of AstraZeneca. The move strategically increases the availability of monoclonal antibodies at a time of ever-increasing demand.
-
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
5/15/2022
Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® in combination with carfilzomib and dexamethasone demonstrated a median progression free survival of 35.7 months, compared to 19.2 months in patients treated with Kd alone, as evaluated by an Independent Review Committee.
-
Press Release: New nirsevimab data analyses reinforce efficacy against RSV
5/11/2022
Results from a prespecified pooled analysis of the pivotal Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy of 79.5% against medically attended LRTI, such as bronchiolitis or pneumonia, caused by RSV in infants born at term or preterm entering their first RSV season.
-
Press Release: Foundation S: Sanofi’s new philanthropic spearhead
5/4/2022
Sanofi launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations.
-
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).
-
Press Release: Annual General Meeting of May 3, 2022
5/3/2022
The Combined General Shareholders’ Meeting of Sanofi was held on May 3, 2022 at Paris Expo Porte de Versailles, under the chairmanship of Serge Weinberg.
-
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
-
The charges come from several in-process research and development projects acquired outside of a business combination.
-
Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.
-
Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
4/14/2022
Positive results from the Phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, in adults with heavily pre-treated immune thrombocytopenia were published in the New England Journal of Medicine.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
-
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
4/7/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has expanded the marketing authorization for Dupixent® in the European Union.
-
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
4/7/2022
The European Commission has expanded the marketing authorization for Dupixent® in the European Union.
-
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
4/4/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis, a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
-
Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
4/4/2022
Sanofi launches its Diversity, Equity & Inclusion Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors.
-
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
4/1/2022
Sanofi announced that the French Autorité des marchés financiers has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.